Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression

Niwa, Koichiro; Onogi, Kokyo; Wu, Yun; Mori, Hideki; Inoue, Yosuke; Tamaya, Teruhiko

doi:10.3892/mmr.1.1.119

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small trial in 28 advanced serous ovarian carcinoma patients found that standard platinum-based chemotherapies augmented with CIM, at a dose of 800 mg/day, commencing 2 weeks before surgery and continuing synchronously with chemotherapy, showed statistically significant improvements in overall survival compared to platinum-based chemotherapy alone [ 66 ].…”

Section: Human Data In Cancermentioning

confidence: 99%

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Pantziarka

Bouche

Meheus

et al. 2014

ecancer

245

View full text Add to dashboard Cite

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

show abstract

Section: Human Data In Cancermentioning

confidence: 99%

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Pantziarka

Bouche

Meheus

et al. 2014

ecancer

245

View full text Add to dashboard Cite

show abstract

H2 antihistamines: May be useful for combination therapies in cancer?

Mohamad,

Galarza,

Martín

2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

Pantziarka

Sukhatme²,

Bouche

et al. 2015

ecancer

102

View full text Add to dashboard Cite

Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti- cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper.

show abstract

Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression

Cited by 3 publications

References 10 publications

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

H2 antihistamines: May be useful for combination therapies in cancer?

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

Contact Info

Product

Resources

About